Phase Ib Study of Afuresertib Combined With Paclitaxel in Pre-treated HER2-negative Advanced Gastric Cancer

Trial Profile

Phase Ib Study of Afuresertib Combined With Paclitaxel in Pre-treated HER2-negative Advanced Gastric Cancer

Completed
Phase of Trial: Phase I

Latest Information Update: 14 Apr 2017

At a glance

  • Drugs Afuresertib (Primary) ; Paclitaxel
  • Indications Gastric cancer
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors GlaxoSmithKline; Novartis
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 07 Apr 2017 Status changed from recruiting to completed.
    • 19 Sep 2016 Planned End Date changed from 1 Mar 2017 to 1 Sep 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top